BACKGROUND: This study aimed to determine whether patients with lower abdominal symptoms can be investigated quickly using results of faecal haemoglobin concentration (f-Hb) measurements, and whether this test could form part of a diagnostic pathway for significant colorectal disease. METHODS: Nine hundred and nine consecutive patients referred from primary care for colonoscopy were invited: 507 submitted samples for f-Hb measurement with a quantitative faecal immunochemical test for haemoglobin (FIT) (HM-JACKarc, Kyowa-Medex, Japan) and a diagnostic colonoscopy was completed in 484 patients. RESULTS: Colorectal cancer (CRC), higher risk adenoma (HRA), inflammatory bowel disease (IBD) and/or colitis was found in 45 patients (9.3%); these had significantly higher (p<0.0001) f-Hb than the group of 243 with normal colonoscopy plus the 196 patients with less significant clinical findings. The 11 (2.2%) patients with CRC all had f-Hb >190 μg Hb/g faeces. Using a f-Hb cut-off of 10 μg Hb/g faeces, for the group with CRC or HRA or IBD or colitis, sensitivity was 68.9%, specificity 80.2%, positive predictive value (PPV) 26.3% and negative predictive value (NPV) 96.2%. Sensitivity and NPV were 100% for CRC suggesting f-Hb is a good rule-in test for CRC. Of the 243 patients with normal colonoscopy, 81.2% had f-Hb<10 μg Hb/g faeces. CONCLUSIONS: The high NPV for significant colorectal diseases suggests that f-Hb could be used as a rule-out test in this context. Potential exists for using f-Hb measurements to investigate symptomatic patients and guide the use of colonoscopy resources: detailed algorithms for the introduction of f-Hb measurements requires further exploration.
BACKGROUND: This study aimed to determine whether patients with lower abdominal symptoms can be investigated quickly using results of faecal haemoglobin concentration (f-Hb) measurements, and whether this test could form part of a diagnostic pathway for significant colorectal disease. METHODS: Nine hundred and nine consecutive patients referred from primary care for colonoscopy were invited: 507 submitted samples for f-Hb measurement with a quantitative faecal immunochemical test for haemoglobin (FIT) (HM-JACKarc, Kyowa-Medex, Japan) and a diagnostic colonoscopy was completed in 484 patients. RESULTS:Colorectal cancer (CRC), higher risk adenoma (HRA), inflammatory bowel disease (IBD) and/or colitis was found in 45 patients (9.3%); these had significantly higher (p<0.0001) f-Hb than the group of 243 with normal colonoscopy plus the 196 patients with less significant clinical findings. The 11 (2.2%) patients with CRC all had f-Hb >190 μg Hb/g faeces. Using a f-Hb cut-off of 10 μg Hb/g faeces, for the group with CRC or HRA or IBD or colitis, sensitivity was 68.9%, specificity 80.2%, positive predictive value (PPV) 26.3% and negative predictive value (NPV) 96.2%. Sensitivity and NPV were 100% for CRC suggesting f-Hb is a good rule-in test for CRC. Of the 243 patients with normal colonoscopy, 81.2% had f-Hb<10 μg Hb/g faeces. CONCLUSIONS: The high NPV for significant colorectal diseases suggests that f-Hb could be used as a rule-out test in this context. Potential exists for using f-Hb measurements to investigate symptomatic patients and guide the use of colonoscopy resources: detailed algorithms for the introduction of f-Hb measurements requires further exploration.
Authors: Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele Journal: Gut Date: 2022-07-12 Impact factor: 31.793
Authors: Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele Journal: Ann Clin Biochem Date: 2021-01-21 Impact factor: 2.057
Authors: Joaquín Cubiella; Pablo Vega; María Salve; Marta Díaz-Ondina; Maria Teresa Alves; Enrique Quintero; Victoria Álvarez-Sánchez; Fernando Fernández-Bañares; Jaume Boadas; Rafel Campo; Luis Bujanda; Joan Clofent; Ángel Ferrandez; Leyanira Torrealba; Virginia Piñol; Daniel Rodríguez-Alcalde; Vicent Hernández; Javier Fernández-Seara Journal: BMC Med Date: 2016-08-31 Impact factor: 8.775
Authors: James L Turvill; Daniel Turnock; Dan Cottingham; Monica Haritakis; Laura Jeffery; Annabelle Girdwood; Tom Hearfield; Alex Mitchell; Ada Keding Journal: Br J Gen Pract Date: 2021-07-29 Impact factor: 6.302
Authors: Mark S Johnstone; Gillian Miller; Grace Pang; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley Journal: Ann Clin Biochem Date: 2022-03-03 Impact factor: 2.587
Authors: Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser Journal: BMC Med Date: 2017-10-24 Impact factor: 8.775